Navigation Links
Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Date:8/5/2008

SHELTON, Conn., Aug. 5 /PRNewswire/-- Cara Therapeutics, Inc. today announced completion of a Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of acute and chronic pain. The drug candidate was safe and well-tolerated after intravenous infusion, and resulted in plasma levels of CR845 expected to be associated with clinical analgesic activity. In addition, CR845 infusion triggered a quantitative endocrine biomarker of peripheral kappa opioid receptor activation at the lowest dose tested.

The Phase Ia single-center clinical trial evaluated the safety, tolerability, pharmacokinetic profile, and pharmacological activity of CR845 in a double-blind, randomized, placebo-controlled, single escalating intravenous dose study in 54 healthy male and female volunteers. CR845 was shown to be safe at all doses investigated, with no reports of serious side effects or adverse central nervous system activity. Linear, dose-proportional increases in systemic exposure to CR845 were observed. Low doses of CR845 resulted in plasma levels at or above the plasma levels of drug expected to be associated with clinical analgesic efficacy.

The Company plans to advance its intravenous formulation of CR845 into Phase II trials later in 2008. Based on the demonstrated safety, tolerability, and bioactivity of this formulation in Phase I, Cara will continue to develop its oral formulation of CR845 for advancement into Phase I.

About CR845

CR845 was designed to be highly selective for the peripheral kappa opioid receptor, with a prolonged duration of action relative to Cara's first generation of peripheral kappa opioids. Animal studies indicate that CR845 is effective in reducing pain of inflammatory, neuropathic and visceral origin. The analgesic and anti-inflammatory effects of CR845 lasted for up to 18 hours after a single dose. CR845 was active after intravenous, subcutaneous, o
'/>"/>

SOURCE Cara Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
5. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
6. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
7. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
8. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
9. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
10. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
11. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
(Date:7/24/2014)... PARK, Kan. , July 24, 2014 /PRNewswire/ ... of two compounds that will be added to ... with Australian-based CIMTECH Pty Ltd, a biotechnology company. ... PAR 122 have shown promise in bone regeneration ... license to develop the compounds for the veterinary ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... , Weltweite Exklusivlizenz ... ermöglicht QIAGEN die Entwicklung von Tests auf ... Blutkrebs  Neuer Test weist Mutationen ... Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... Corporation (NYSE: GPX ), a global ... technical training, e-Learning solutions, management consulting and engineering services, ... Esposito-Mayer will speak at the ROTH Capital Partners 24th ... PT. The conference will be held at The Ritz ...
... and NEW YORK, March 6, 2012   Access ... leveraging its proprietary drug-delivery platforms to develop treatments in ... lead product website, www.MuGard.com , with a new ... visit the Testimonials section of the MuGard site or ...
Cached Medicine Technology:Access Pharmaceuticals Updates MuGard.com With New Product Testimonial 2Access Pharmaceuticals Updates MuGard.com With New Product Testimonial 3
(Date:7/25/2014)... (PRWEB) July 25, 2014 Consuming too ... How to know? , Read the labels! , Learn ... determine how it relates to health during a "Healthy ... Aug. 1 at Humility House, 755 Ohltown Road, Austintown. ... lead an informational discussion and answer questions. , ...
(Date:7/25/2014)... City, UT (PRWEB) July 25, 2014 ... court surfaces for the recent Nike National Invitational ... the current United States Junior National Tournament (USJN) ... July 25. , The flooring for these prestigious national ... more than 300,000 square feet of playing surface at ...
(Date:7/25/2014)... 2014 As reported by People Magazine in ... Jersey Shore and Getting Sober (7/15), one of the ... has spoken out to the public about his personal transformation. ... The Situation admits that moving on with his life was ... and other drugs in 2012 and even spent some time ...
(Date:7/25/2014)... July 25, 2014 (HealthDay News) -- The human brain ... of dehydration, a new study finds. Although ... in England have found that the brain compensates by ... blood. "This research has helped us understand a ... extreme exercise in extreme conditions," study first author Steven ...
(Date:7/25/2014)... Art of Facial Surgery has recently stepped up ... who are looking for minor touch-ups to make them more ... American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) ... surgery showed a surprising increase between 2012 and 2013. ... transplants increased by 7 percent and eyelid surgery increased by ...
Breaking Medicine News(10 mins):Health News:Learn to Decipher Food Labels at Humility House 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 3
... , , , ... Dr. Raymond Boyle, Ph.D., M.P.H., will be the new Director of ... and Epidemiology from the University of Oregon and the University of ... this new addition to ClearWay Minnesota and our research department," said ...
... explain why some function fine on six hours a night , ... by just fine on six hours of sleep, and a new ... finding doesn,t appear likely to help people with insomnia. Still, it ... long as they do, said study co-author Ying-Hui Fu, a professor ...
... Aug. 13 The following statement was released today by United ... comprehensive health care has been a high priority for the disability ... Act (H.R. 3200) will make significant strides toward meeting that goal. ... , Major insurance market reforms such as ...
... , BASKING RIDGE, N.J., Aug. 13 ... record-keeping, protecting confidential patient information becomes vastly more complex. ... designed to help safeguard the growing exchange of electronic patient ... , The first offering, Verizon Security Management ...
... , , , , ... busy preparing their children for departure for school, it is just ... from bringing bed bugs home from college and their travels. ... in the New York Metropolitan area, has seen a significant increase ...
... , MIAMI BEACH, Fla., Aug. 13 Centers ... facilities in Florida at the Florida Health Care Conference in Hollywood, ... for pressure ulcer management from the Florida Agency for Health Care ... Weaver, Chief of Field Operations, Division of Managed Care and Health ...
Cached Medicine News:Health News:They Snooze Less, But They Don't Lose 2Health News:Verizon Introduces New IT Security Capabilities for Health Care Industry 2Health News:Verizon Introduces New IT Security Capabilities for Health Care Industry 3Health News:Verizon Introduces New IT Security Capabilities for Health Care Industry 4Health News:Bed Bug Epidemic and Upcoming School Breaks Could Wreak Havoc on Homeowners 2Health News:Bed Bug Epidemic and Upcoming School Breaks Could Wreak Havoc on Homeowners 3Health News:Centers of Excellence Awards Presented to Over 100 Nursing Facilities as Nursing Facilities Reach the 'Tipping Point' in Treating Pressure Ulcers 2
... knee manufacturers focus attention on implant design, ... The Profix Total Knee System seeks to ... implant system and the tools to implant ... widely recognized for innovation in total knee ...
Cruciate retaining, posterior stabilized and constrained components....
Cruciate retaining, posterior stabilized and constrained components....
Maximum contact. Minimum wear. Outstanding results....
Medicine Products: